Ensysce Biosciences provides takeaways from Geoff Birkett, the Company’s CCO, following his participation on the opening panel of the European Pharmaceutical Market Research Association Annual Conference in London on June 25. Geoff Birkett discussed “The Future of Healthcare Research” with industry partners and underlined the importance of new healthcare technologies to address key problems for patients and the companies that serve them. Ensysce’s TAAP and MPAR platforms, which have been developed through advanced technology for the treatment of pain, are good examples of next generation healthcare due to the advanced chemistry and research that has supported their development. Mr. Birkett also acted as convenor of a key presentation titled, “Applying a human approach to strategy development” on Wednesday, June 26th, where presenters debated how best to ensure that company staff and prescribers have an active role in drug development to maximize product impact. This was an interesting session in a meeting where AI was a prominent theme, and in the future, there will be a premium on combining AI and HI in the best way.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSC:
- Ensysce Biosciences announces partnership with Purisys for PF9001
- Ensysce Biosciences selects PF9001 to move into IND-enabling studies
- Ensysce Biosciences regains compliance with Nasdaq
- Ensysce Biosciences renews collaboration with Quotient Sciences
- Ensysce Biosciences reports Q1 EPS (55c) vs. ($2.08) last year